Drawing a tube of blood could assess ALS risk from environmental toxin exposure

The risk score included 36 pollutants persistently found in the environment

5:00 AM

Author | Noah Fromson

vial of blood in container lab blue yellow grainy graphic
Jacob Dwyer, Justine Ross, Michigan Medicine

Over the last decade, research at Michigan Medicine has shown how exposure to toxins in the environment, such as pesticides and carcinogenic PCBs, affect the risk of developing and dying from amyotrophic lateral sclerosis. 

Now, investigators have developed an environmental risk score that assesses a person’s risk for developing ALS, as well as for survival after diagnosis, using a blood sample.

The results are published in the Journal of Neurology, Neurosurgery and Psychiatry.

SEE ALSO: Early Pesticide Exposure Contributes to Faster ALS Progression

“For the first time, we have a means collecting a tube of blood and looking at a person’s risk for ALS based on being exposed to scores of toxins in the environment,” said first author Stephen Goutman, M.D., M.S., director of the Pranger ALS Clinic and associate director of the ALS Center of Excellence at University of Michigan.

Researchers obtained over 250 blood samples from participants in Michigan both with and without ALS. They calculated individual risk and survival models using 36 persistent organic pollutants.

Several individual pollutants were significantly associated with ALS risk. However, the risk for developing the disease was most strongly represented by a mixture of pesticides in the blood.

SEE ALSO: ALS risk higher among production workers, those exposed to metals, volatile compounds on job

When considering the mixture of these pollutants, a person who was in the highest group of exposure had twice the risk of developing ALS compared to someone in the lowest group of exposure.

Our results emphasize the importance of understanding the breadth of environmental pollution and its effects on ALS and other diseases,” said senior author Eva Feldman, M.D., Ph.D., James W. Albers Distinguished Professor at U-M, the Russell N. DeJong Professor of Neurology at U-M Medical School and director of the NeuroNetwork for Emerging Therapies at Michigan Medicine.

The research team’s first understanding of the environment’s impact on ALS came in 2016 when investigators found elevated levels of pesticides in the blood of patients with the disease.

They later uncovered that exposure to organic pollutants advances ALS progression and contributes to worse outcomes.

“When we can assess environmental pollutants using available blood samples, that moves us toward a future where we can assess disease risk and shape prevention strategies,” Feldman said.

“Environmental risk scores have been robustly associated with other diseases, including cancers, especially when coupled with genetic risk. This is a burgeoning application that should be further studied as we deal with the consequences of pollutants being detected throughout the globe.”

Additional authors include Jonathan Boss, Dae-Gyu Jang, Ph.D., Bhramar Mukherjee, Ph.D., Rudy J. Richardson, Ph.D., and Stuart Batterman, Ph.D., all of University of Michigan.

This research was supported by the National ALS Registry/Agency for Toxic Substances and Disease Registry at the CDC (grants 1R01TS000289, CDC/ATSDR 200-2013-56856).

This research was also supported by the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Environmental Health Sciences and the National Center for Advancing Translational Sciences at the National Institutes of Health (grants K23ES027221, R01ES030049, R01NS127188, UL1TR002240). Additional support from the NeuroNetwork for Emerging Therapies, the NeuroNetwork Therapeutic Discovery Fund, the Peter R. Clark Fund for ALS Research, the Sinai Medical Staff Foundation, and Scott L. Pranger, University of Michigan.

Paper cited: “Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort,” Journal of Neurology, Neurosurgery and Psychiatry. DOI: 10.1136/jnnp-2023-332121


More Articles About:

All Research Topics Basic Science and Laboratory Research Lou Gehrig's (ALS) Neurological (Brain) Conditions Neurodegenerative Disorder Neurological Disorders Occupational Health
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Girl with Down syndrome sleeping in bed
Health Lab

Treating obstructive sleep apnea in children with Down syndrome

Sleep experts discuss why early treatment matters, the limitations of current therapies, and research opportunities to improve treatment of obstructive sleep apnea in children with Down syndrome.
presentation on stage with slideshow up
Health Lab

Medical students develop novel technological solutions for unmet patient needs

University of Michigan medical students showcased AI-driven healthcare innovation projects focused on melanoma support, transplant recovery and primary care access.
pill in child's hand blue sweater
Health Lab

More leucovorin prescribed to kids after federal officials touted its unproven benefits for autism

A new study finds sharp increase in dispensing of leucovorin after high profile news conference touting its unproven benefits for autism.
small bacteria cells floating on blue background reddish tint
Health Lab

Study overturns 100-year-old assumption about common bacteria in the lungs

A new U-M study overturns a 100-year-old assumption about one common bacterial resident of the lungs, Prevotella melaninogenica.
cancer cell floating with yellow dots drawn out blue
Health Lab

Biomarkers aid cost-benefit analysis of head and neck cancer immunotherapy

The cost-effectiveness of the immunotherapy drug pembrolizumab for patients with locally advanced head and neck squamous cell carcinoma may depend on biomarker results, according to a new study by Michigan Medicine.
woman on phone taking notes
Health Lab

7 things every family caregiver should know – but many don’t

A guide to many community resource, and state and federal programs, that University of Michigan polls show caregivers to older adults and people with disabilities often don’t know about.